▲ +159.91% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for DiaMedica Therapeutics in the last 3 months. The average price target is $23.83, with a high forecast of $38.00 and a low forecast of $14.00. The average price target represents a 159.91% upside from the last price of $9.17.
The current consensus among 5 investment analysts is to buy stock in DiaMedica Therapeutics. This Buy consensus rating has held steady for over two years.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which has completed Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.